Mark Leuchtenberger

48 years old

Mr. Leuchtenberger has been a member of the Board of Directors of EPIX since September 2004. Mr. Leuchtenberger is the President & CEO of Therion Biologics, a privately held biotechnology company developing therapeutic vaccines for cancer. Prior to joining Therion in 2002, Mr. Leuchtenberger spent 11 years at Biogen, Inc., where he led the development and launch of AvonexB. and ran North American and international commercial operations. Mr. Leuchtenberger also serves on boards for the Massachusetts Biotechnology Council, Beth Israel Deaconess Medical Center and Wake Forest University. read more ...
  • healthcare
  • Diagnostic Substances

Public Records

Arrest Records

Possible Social Links

Scroll